Latest database descriptions

General objective: A prospective evaluation characterising age-related bone loss in men at different skeletal sites. Identification of clinical, biochemical and hormonal determinants of bone loss and fractures with the aid of biochemical markers.

To investigate the impact of transdermal oestrogens and other menopause treatments on the risk of recurrent venous thrombosis.

General objective: to better understand the physiopathology of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) associated with HIV by studying, on the one hand, interaction between Epstein-Barr virus (EBV) and HIV infection from a virological and immunological viewpoint and, on the other hand, the role of chronic antigen stimulation. Secondary objectives: - Clinical and histological characterisation of lymphoma; - to undertake an observational study on the treatment and outcome for these patients in terms of antiretroviral therapy; - to create a forum concerning therapeutic care for these patients; - To enable "Lymphoma and HIV" studies developed by the ANRS group: (1) Clinical: (a) To define prognostic factors for unfavourable progression of NHL and HL (b) To develop target treatment consensus according to histology and clinical presentation for patients included in the cohort (2) Anatomical and clinical: to characterise lymphoproliferations and investigate the presence and reactivation of EBV in these tumours (3) Immunological: to study anti-EBV immune T cell response and their role in the pathophysiology of EBV-related lymphomas, to characterise the activation status of circulating B cells (4) Virological: to quantify viral load and anti-EBV antibody titres, to genotype EBV variants for HL patients, to study the replication of EBV in B lymphocyte memory, to investigate the interaction of TGF-induced EBV replication and cell survival in tumour cells infected by EBV (5) Molecular: to study the "microsatellite instability" (MSI) phenotype of these tumours.

General objective: 1. To follow a national cohort of children from their first episode of acute demyelination and monitor them for over 10 years 2. To determine the clinical and radiological risk factors of recurrence (qualified by MS diagnosis) 3. To determine the progression towards disability and its risk factors 4. To participate in a genetic study regarding MS susceptibility 5. Pharmacovigilance (vaccines)